Nostrum Laboratories Extended-release Metformin Recalled Due to N-nitrosodimethylamine (NDMA) Contamination
According to cardiovascularbusiness.com, the FDA announced one more recall of extended-release (ER) metformin. Nostrum Laboratories’ metformin was recalled due to an unacceptable level of N-nitrosodimethylamine (NDMA). N-nitrosodimethylamine (NDMA) is a known carcinogen.
Nostrum Laboratories, a medication manufacturer, based in Kansas City, Missouri, announced the recall this week. Nostrum Laboratories is recalling two lots of their ER metformin tablets. According to the Nostrum Laboratories press release, these tablets were distributed to pharmaceutical wholesalers across the United States. The affected drug lot numbers are MET200101 and MET200301. As part of the recall process, Nostrum Laboratories is in the process of notifying all distributors by letter that detail how the distributor can return the recalled tablets.
According to the press release, Nostrum Laboratories recommends that patients taking metformin should discuss the matter with their healthcare professionals for either a replacement or to receive a different treatment alternative. Nostrum Laboratories also stated that it is too dangerous for patients with type 2 diabetes to discontinue using their metformin medication without first talking to their doctor.
N-nitrosodimethylamine (NDMA) has been linked to reports of colorectal cancer, stomach cancer, liver cancer and several other types of cancers along the digestive tract when the patient has been taking contaminated metformin for several months.
If you or a loved one suffered severe side effects or developed cancer while taking metformin, contact Parker Waichman LLP online or by calling 1-800-YOUR-LAWYER (1-800-968-7529) for your free consultation.
New York | Brooklyn | Queens | Long Island | New Jersey | Florida
Call us at: 1-800-YOURLAWYER (800-968-7529) | Schedule your free consultation